1) The PrEP example in Module 10 highlighted how product introduction and scale-up can differ according to factors such as the country’s health systems, regulatory approval processes, and the availability of financial, human and other resources. Reflect on your setting and think about the potential process for introduction and possible scale-up of an efficacious microbicide (e.g., tenofovir gel or dapivarine ring). Describe what might be similar or different to the PrEP timeline
For my experience of iPrEx and MTN study, PrEP in Thailand not well known in general population. I think only people who work in this area that understanding about PrEP, especially in MSM/TG. If anyone interest to use PrEP, they need to pay by themselves. However, government have interested about PrEP. Hope they have policy to support PrEP soon.
2) Describe ways you have engaged stakeholders (or been engaged as a stakeholder) in results dissemination for a trial and/or possible future access of a trial product. What were some of the challenges? Are there lessons learned you might share?
We had been dissemination iPrEx result to all stakeholders. No problem for us to provide information. iPrEx team have great preparation plan and share to each site. We have communication plan for this step. We set time point to share result in step by step and set target for releasing news. I think that only media that difficult. We prepare news release to media but in real situation we found that many website copy and developing some content that error and miss some information. This is good experience for our team about awareness to providing information to media.
